Literature DB >> 22855800

Beneficial effects of Nrf2 overexpression in a mouse model of Alexander disease.

Christine M LaPash Daniels1, Elizabeth V Austin, Danica E Rockney, Elizabeth M Jacka, Tracy L Hagemann, Delinda A Johnson, Jeffrey A Johnson, Albee Messing.   

Abstract

Alexander disease is a fatal neurodegenerative disease caused by dominant mutations in glial fibrillary acidic protein (GFAP). The disease is characterized by protein inclusions called Rosenthal fibers within astrocyte cell bodies and processes, and an antioxidant response mediated by the transcription factor Nrf2. We sought to test whether further elevation of Nrf2 would be beneficial in a mouse model of Alexander disease. Forcing overexpression of Nrf2 in astrocytes of R236H GFAP mutant mice decreased GFAP protein in all brain regions examined (olfactory bulb, hippocampus, cerebral cortex, brainstem, cerebellum, and spinal cord) and decreased Rosenthal fibers in olfactory bulb, hippocampus, corpus callosum, and brainstem. Nrf2 overexpression also restored body weights of R236H mice to near wild-type levels. Nrf2 regulates several genes involved in homeostasis of the antioxidant molecule glutathione, and the neuroprotective effects of Nrf2 in other neurological disorders may reflect restoration of glutathione to normal levels. However, glutathione levels in R236H mice were not decreased. Nrf2 overexpression did not change glutathione levels or ratio of reduced to oxidized glutathione (indicative of oxidative stress) in olfactory bulb, where Nrf2 dramatically reduced GFAP. Depletion of glutathione through knock-out of the GCLM (glutamate-cysteine ligase modifier subunit) also did not affect GFAP levels or body weight of R236H mice. These data suggest that the beneficial effects of Nrf2 are not mediated through glutathione.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855800      PMCID: PMC3448488          DOI: 10.1523/JNEUROSCI.1494-12.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  34 in total

1.  Neuronal sensitivity to kainic acid is dependent on the Nrf2-mediated actions of the antioxidant response element.

Authors:  Andrew D Kraft; Jong-Min Lee; Delinda A Johnson; Yuet Wai Kan; Jeffrey A Johnson
Journal:  J Neurochem       Date:  2006-09       Impact factor: 5.372

2.  Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription.

Authors:  Marcus J Calkins; Rebekah J Jakel; Delinda A Johnson; Kaimin Chan; Yuet Wai Kan; Jeffrey A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

3.  High-performance liquid chromatography of thiols and disulfides: dinitrophenol derivatives.

Authors:  M W Fariss; D J Reed
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

4.  Astrocyte-specific overexpression of Nrf2 protects striatal neurons from mitochondrial complex II inhibition.

Authors:  Marcus J Calkins; Marcelo R Vargas; Delinda A Johnson; Jeffrey A Johnson
Journal:  Toxicol Sci       Date:  2010-03-08       Impact factor: 4.849

5.  Synergistic effects of the SAPK/JNK and the proteasome pathway on glial fibrillary acidic protein (GFAP) accumulation in Alexander disease.

Authors:  Guomei Tang; Zhiheng Xu; James E Goldman
Journal:  J Biol Chem       Date:  2006-10-10       Impact factor: 5.157

6.  An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.

Authors:  K Itoh; T Chiba; S Takahashi; T Ishii; K Igarashi; Y Katoh; T Oyake; N Hayashi; K Satoh; I Hatayama; M Yamamoto; Y Nabeshima
Journal:  Biochem Biophys Res Commun       Date:  1997-07-18       Impact factor: 3.575

7.  Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription.

Authors:  Marcus J Calkins; Jessica A Townsend; Delinda A Johnson; Jeffrey A Johnson
Journal:  Exp Neurol       Date:  2010-04-18       Impact factor: 5.330

8.  Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis.

Authors:  Marcelo R Vargas; Delinda A Johnson; Daniel W Sirkis; Albee Messing; Jeffrey A Johnson
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

9.  Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis.

Authors:  Jong-Min Lee; Marcus J Calkins; Kaimin Chan; Yuet Wai Kan; Jeffrey A Johnson
Journal:  J Biol Chem       Date:  2003-01-28       Impact factor: 5.157

10.  GFAP mutations, age at onset, and clinical subtypes in Alexander disease.

Authors:  M Prust; J Wang; H Morizono; A Messing; M Brenner; E Gordon; T Hartka; A Sokohl; R Schiffmann; H Gordish-Dressman; R Albin; H Amartino; K Brockman; A Dinopoulos; M T Dotti; D Fain; R Fernandez; J Ferreira; J Fleming; D Gill; M Griebel; H Heilstedt; P Kaplan; D Lewis; M Nakagawa; R Pedersen; A Reddy; Y Sawaishi; M Schneider; E Sherr; Y Takiyama; K Wakabayashi; J R Gorospe; A Vanderver
Journal:  Neurology       Date:  2011-09-14       Impact factor: 11.800

View more
  19 in total

1.  Exploiting metabolic and antioxidant pathways to maintain vision in blinding disease.

Authors:  Pavitra S Ramachandran; Ji Yun Song; Jean Bennett
Journal:  J Clin Invest       Date:  2015-03-23       Impact factor: 14.808

2.  Ceftriaxone for Alexander's Disease: A Four-Year Follow-Up.

Authors:  GianPietro Sechi; Isabella Ceccherini; Tiziana Bachetti; Giovanni A Deiana; Elia Sechi; Pietro Balbi
Journal:  JIMD Rep       Date:  2012-10-13

3.  Glial fibrillary acidic protein exhibits altered turnover kinetics in a mouse model of Alexander disease.

Authors:  Laura R Moody; Gregory A Barrett-Wilt; Michael R Sussman; Albee Messing
Journal:  J Biol Chem       Date:  2017-02-21       Impact factor: 5.157

4.  High-Throughput Screening for Drugs that Modulate Intermediate Filament Proteins.

Authors:  Jingyuan Sun; Vincent E Groppi; Honglian Gui; Lu Chen; Qing Xie; Li Liu; M Bishr Omary
Journal:  Methods Enzymol       Date:  2015-11-19       Impact factor: 1.600

5.  Role of major and brain-specific Sgce isoforms in the pathogenesis of myoclonus-dystonia syndrome.

Authors:  Jianfeng Xiao; Satya R Vemula; Yi Xue; Mohammad M Khan; Francesca A Carlisle; Adrian J Waite; Derek J Blake; Ioannis Dragatsis; Yu Zhao; Mark S LeDoux
Journal:  Neurobiol Dis       Date:  2016-11-24       Impact factor: 5.996

6.  GFAP expression as an indicator of disease severity in mouse models of Alexander disease.

Authors:  Paige L Jany; Tracy L Hagemann; Albee Messing
Journal:  ASN Neuro       Date:  2013       Impact factor: 4.146

7.  Anastasis Drives Senescence and Non-Cell Autonomous Neurodegeneration in the Astrogliopathy Alexander Disease.

Authors:  Liqun Wang; Hassan Bukhari; Linghai Kong; Tracy L Hagemann; Su-Chun Zhang; Albee Messing; Mel B Feany
Journal:  J Neurosci       Date:  2022-02-01       Impact factor: 6.709

8.  Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease.

Authors:  Christine M LaPash Daniels; Elizabeth Paffenroth; Elizabeth V Austin; Konstantin Glebov; Diana Lewis; Jochen Walter; Albee Messing
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

9.  Mechanisms of Nrf2 protection in astrocytes as identified by quantitative proteomics and siRNA screening.

Authors:  James A Dowell; Jeffrey A Johnson
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

Review 10.  Cytoprotection "gone astray": Nrf2 and its role in cancer.

Authors:  Claudia Geismann; Alexander Arlt; Susanne Sebens; Heiner Schäfer
Journal:  Onco Targets Ther       Date:  2014-08-26       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.